Society for Immunotherapy of Cancer (SITC)
Elie G. Dib, MD, MS, FACP, currently serves as the Associate Program Director of the Hematology Oncology Fellowship Program at Trinity Health MI since July 2018 and is a Hematologist Oncologist at IHA. Additional roles include Course Director for the Society for Immunotherapy of Cancer (SITC) and NCORP Representative on the NCI Genitourinary Cancers Steering Committee. Dib is also involved with the American Society of Clinical Oncology (ASCO) in various capacities, including serving as a member of the Molecular Tumor Board and Associate Editor for ASCO-SEP. As an Adjunct Faculty member at Johns Hopkins University, Dib teaches Cancer Genomics. Educational qualifications include a Master's degree in Individualized Genomics and Health from Johns Hopkins University and a postgraduate program in Cancer Biology & Therapeutics from Harvard Medical School.
This person is not in any teams
This person is not in any offices
Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. sitc_log_color.png Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world. Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.